Oncology News

Women with a history of ductal carcinoma in situ reported confusion and concern about diagnosis and treatment of the noninvasive breast condition, according to results of a national web-based survey published in Cancer.

Fam-trastuzumab deruxtecan-nxki improved outcomes among patients with HER2-low unresectable or metastatic breast cancer, according to topline data released by the agent’s manufacturer.

Initial breast cancer care across the United States is inconsistent, which is largely attributed to regional factors rather than patient factors, according to data published in JAMA Oncology.

Use of aspirin failed to prolong invasive DFS among patients with breast cancer, according to results of a randomized phase 3 study presented during the ASCO Plenary Series.

Breast cancer has surpassed lung cancer as the leading cause of cancer-associated death among Black women in the U.S., according to an American Cancer Society report.

Cemiplimab extended OS compared with single-agent chemotherapy for women with recurrent cervical cancer, according to randomized phase 3 study results published in The New England Journal of Medicine.

Selinexor prolonged PFS compared with placebo among women with advanced or recurrent endometrial cancer, according to topline data released by the agent’s manufacturer.

Trametinib should be a new standard of care for women with recurrent low-grade serous carcinoma, according to study published in The Lancet that showed a 52% reduction in risk for disease progression or death vs. current treatment options.

The COVID-19 pandemic had significant repercussions on the health care system. As lockdowns went into effect, patients postponed, canceled or simply did not make needed medical appointments.

Lenvatinib plus pembrolizumab conferred significantly longer PFS and OS than chemotherapy among women with advanced endometrial cancer, according to randomized, phase 3 trial results published in The New England Journal of Medicine.